Enroll or Get More Info

Valleywise Health is currently enrolling women in an important clinical trial for breast cancer screening. Enroll today. Help breast cancer patients tomorrow.

About the Trial:

The TMIST is a randomized breast screening trial that is sponsored by the National Cancer Institute. The study is designed to help researchers determine which of two FDA-approved mammograms are best for cancer screening and identification: digital mammography (2D) or tomosynthesis mammography (3D). The 2D takes images from two sides of the breast to create a flat image, the 3D takes images from different angles around the breast and then builds a 3D-like image.

Why it Matters:

Researchers are doing this large international trial because it’s not clear whether 3D mammography is better than 2D mammography for breast cancer screening and early cancer diagnosis. This important study may determine what kind of mammograms are given to screen women in the future.

Who Can Enroll:

Women ages 45 to 74 who are planning to get a routine screening mammogram are invited to contact us to see if they are eligible to participate.

What Participants Can Expect:

Once enrolled in the trial, women will be randomly assigned by a computer to get either 3D or 2D screening mammograms for five years. Each woman will be told how often to get screened during the five years; this could be either every year or every other year based on her individual risk factors.

In addition to having a mammogram (either 2D or 3D), all women who join the trial will be asked to submit tissue samples, if they have a biopsy or surgery on their breasts.

Get More Information

Principal Investigator
Christina R. Ferraro, MD

Lead Coordinator
Blanca Flor Jimenez, PhD

Phone
602-344-1602 (x41602)